Cargando…
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, relating largely to the clinical advances that have been associated with the development of monoclonal antibodies targeting the immune inhibitory co-receptors CTLA-4 and PD-1 and to the pursuit of gene...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668483/ https://www.ncbi.nlm.nih.gov/pubmed/23511566 http://dx.doi.org/10.1038/bjc.2013.117 |